Search Result

Results for "

FLT

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FLT3 (198) AAK1 (1) ADC Antibody (1) Akt (4) AMPK (1) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (83) Aurora Kinase (11) Autophagy (26) Bcr-Abl (12) Btk (2) c-Fms (10) c-Kit (33) c-Met/HGFR (11) CaMK (1) Casein Kinase (1) Caspase (3) CDK (16) Checkpoint Kinase (Chk) (3) Cytochrome P450 (1) DAPK (1) Discoidin Domain Receptor (4) DNA/RNA Synthesis (1) Drug Metabolite (1) EGFR (5) Ephrin Receptor (1) ERK (1) FAK (1) Ferroptosis (6) FGFR (17) Haspin Kinase (2) HDAC (7) IAP (1) IFNAR (1) IRAK (2) Isotope-Labeled Compounds (6) JAK (21) Ligands for Target Protein for PROTAC (4) LIM Kinase (LIMK) (1) MAP4K (2) MEK (2) MELK (2) Microtubule/Tubulin (1) MNK (1) NO Synthase (2) Orthopoxvirus (1) PDGFR (35) Pim (2) PKA (1) PKC (3) Polo-like Kinase (PLK) (1) PROTACs (10) RAD51 (2) Raf (6) RET (11) ROS Kinase (2) Salt-inducible Kinase (SIK) (1) Small Interfering RNA (siRNA) (10) Src (6) STAT (4) Syk (11) TAM Receptor (12) Target Protein Ligand-Linker Conjugates (1) Tie (1) Topoisomerase (1) Trk Receptor (8) ULK (1) VEGFR (55)
By Research Areas:	Cancer (250) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (24) Metabolic Disease (1) Neurological Disease (2)
Oligonucleotides:	Pre-designed siRNA Sets (10) siRNAs (10)

268

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: FLT3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1516

Alovudine 3'-Fluoro-3'-deoxythymidine; 3′-Deoxy-3′-fluorothymidine; FLT	DNA/RNA Synthesis Orthopoxvirus	Infection Cancer
Alovudine (3'-Fluoro-3'-deoxythymidine) is a marker of DNA synthesis that is less susceptible to inflammatory changes than ¹⁸F-Fluorodeoxyglucose (FDG) and thus is a better biomarker in pancreatic cancer. Alovudine shows anti-orthopoxvirus activity .

HY-128572

FLT3-IN-6	FLT3	Cancer
FLT3-IN-6 is a potent and selective inhibitor of *FLT3-ITD* (FLT3 mutation) with an IC₅₀ of 1.336 nM .

HY-134481

FLT3-IN-10	FLT3	Cancer
FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 has the potential for the research of FLT3-mutated acute myeloid leukemia (AML) .

HY-162032

FLT3-IN-25	FLT3	Cancer
FLT3-IN-25 (compound 17) is a potent inhibitor of *FLT3, with IC₅₀s of 1.2 nM, 1.4 nM and 1.1 nM for FLT3-WT, FLT3-D835Y and FLT3-ITD, respectively. FLT*3-IN-25 plays an important role in acute myeloid leukemia (AML) .

HY-144777

FLT3-IN-14	FLT3 Apoptosis	Cancer
FLT3-IN-14 is a potent *FLT3* inhibitor with IC₅₀s of 5.6 nM and 1.4 nM for FLT3-WT and FLT3-ITD. FLT3-IN-14 reduces the phosphorylation of FLT3 (Y591), induces cell cycle arrest at G1 phase and apoptosis. FLT3-IN-14 significantly reduces the tumor growth in an MV4-11 xenograft mouse model .

HY-156410

FLT3-IN-23	FLT3	Cancer
FLT3-IN-23 (compound 15) is an inhibitor of JFMS-like tyrosine kinase 3 (FLT3) with an IC₅₀ of 7.42 nM. FLT3-IN-23 has antiproliferative activities against BaF3 cells carrying various FLT3-TKD and FLT3-ITD-TKD mutations .

HY-155770

FLT3-IN-20	FLT3	Cancer
FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor with IC₅₀ values of 1 and 4 nM for FLT3-D835Y and FLT3-ITD, respectively. FLT3-IN-20 has anti-proliferation efficacy in FLT3-ITD-positive AML cell lines MV4-11 and MOLM-13 (7 and 9 nM, respectively) and the MOLM-13 variant (4 nM) with the FLT3-ITD-D835Y mutation. FLT3-IN-20 can be used in research of cancer .

HY-148522

FLT3-IN-18	FLT3	Cancer
FLT3-IN-18 is a potent and selective *FLT3* inhibitor with an IC₅₀ value of 0.003 μM. FLT3-IN-18 induces apoptosis and cell cycle arrest at G1 phase. FLT3-IN-18 inhibits FLT3 and STAT5 phosphorylation. FLT3-IN-18 has the potential for the research of acute myeloid leukemia (AML) .

HY-112475

Flt-3 Inhibitor III	Tie FLT3	Cancer
Flt-3 Inhibitor III is a potent and selective FLT3 kinase inhibitor with an ₅₀ of 50 nM. Flt-3 Inhibitor III shows less active against other kinases. Flt-3 Inhibitor III has anticancer effects .

HY-146886

FLT3-IN-15	FLT3	Cancer
FLT3-IN-15 is a highly potent and orally active *FLT3* inhibitor with IC₅₀s of 0.87 nM and 0.32 nM for FLT3 and FLT3/D835Y, respectively. FLT3-IN-15 can be used for researching acute myeloid leukemia .

HY-155302

FLT3-IN-22	FLT3	Cancer
FLT3-IN-22 (compound 22f) is a potent *FLT3* inhibitor with IC₅₀ values of 0.941 nM and 0.199 nM for FLT3 and FLT3/D835Y, respectively. FLT3-IN-22 exhibits strong antiproliferative activity against MV4-11 cells and the mutant FLT kinase expressed Ba/F3 cell lines, including FLT-D835Y and FLT3-F691L .

HY-112145

FLT3-IN-3 2 Publications Verification	FLT3	Cancer
FLT3-IN-3 is a potent *FLT3* inhibitor with IC₅₀s of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively.

HY-143895

FLT3-IN-12	FLT3	Cancer
FLT3-IN-12 is a potent, selective and orally active FLT3 kinase inhibitor with IC₅₀s of 1.48 nM and 2.87 nM for *FLT3-WT* and *FLT3-D835Y, respectively. FLT3-IN-12 possesses high selectivity over c-KIT (>1000-fold). FLT3-IN-12 has an excellent anti-AML (acute myeloid leukemia) activity (MV4-11, IC₅₀* of 0.75 nM) .

HY-148036

FLT3-IN-16	FLT3	Cancer
FLT3-IN-16 is a potent *FLT3* inhibitor with an IC₅₀ of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia .

HY-143894

FLT3-IN-11	FLT3	Cancer
FLT3-IN-11 (compound 30) is a potent, selective and orally active FLT3 kinase inhibitor with IC₅₀s of 7.22 nM and 4.95 nM for wild-type FLT3 and *FLT3-D835Y, respectively. FLT3-IN-11 high selectivity for FLT3 over c-KIT (>1000-fold). FLT*3-IN-11has excellent anti-acute myeloid leukemia (AML) activity (MV4-11 cells, IC₅₀ of 3.2 nM) .

HY-153473

FLT3-IN-19	FLT3	Cancer
FLT3-IN-19 (Comp 50) is a potent and selective *FLT3* inhibitor with IC₅₀ of 0.213 nM. FLT3-IN-19 can be used in AML disease research .

HY-163068

FLT3-IN-24	FLT3	Cancer
FLT3-IN-24 (compound 24) is a potent and selective inhibitor of FLT3 kinase with an IC₅₀ of 7.94 nM. FLT3-IN-24 has cell antiproliferative effects .

HY-144710

FLT3/ITD-IN-2	FLT3	Cancer
FLT3/ITD-IN-2 (Compound 17) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 0.3, 0.4 and 1.0 nM against FLT3 ^D835Y, *FLT3* and FLT3-ITD, respectively. FLT3/ITD-IN-2 potently inhibits the phosphorylation of FLT3 and displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-144711

FLT3/ITD-IN-3	FLT3	Cancer
FLT3/ITD-IN-3 (Compound 19) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 0.3, 0.4 and 0.9 nM against FLT3 ^D835Y, *FLT3* and FLT3-ITD, respectively. FLT3/ITD-IN-3 potently inhibits the phosphorylation of FLT3 and displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-168213

FLT3-IN-27	FLT3	Cancer
FLT3-IN-27 (compound 49) is a *FLT3-ITD* inhibitor with the IC₅₀ of 174 nM. FLT3-IN-27 inhibits cell growth and increases the number of cells in the G1 phase of the cell cycle and can be used for study of acute myeloid leukemia .

HY-144709

FLT3/ITD-IN-1	FLT3	Cancer
FLT3/ITD-IN-1 (Compound 1) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 38.2 nM and 144.1 nM against *FLT3* and FLT3-ITD, respectively. FLT3/ITD-IN-1 displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-148070

FLT3-IN-17	FLT3 FAK Cytochrome P450	Cancer
FLT3-IN-17 inhibits CYPs and *FLT3* mutants activity (IC₅₀s: <0.5 nM for D835Y). FLT3-IN-17 is also a FAK inhibitor, with an IC₅₀ value of 12 nM. FLT3 ligand-2 can be used in the research of cancers .

HY-155226

FLT3-IN-21	FLT3 Apoptosis	Cancer
FLT3-IN-21 (compound LC-3) is a potent FLT3 inhibitor (IC₅₀: 8.4 nM) and induces apoptosis. FLT3-IN-21 can arrest the cell cycle in the G1 phase and inhibit the proliferation of FLT3-ITD-positive AML cells MV-4-11 (IC₅₀: 5.3 nM). In mice, FLT3-IN-21 (10 mg/kg/d) inhibited tumor growth in the MV-4-11 xenograft model (TGI=92.16%) .

HY-146749

FLT3/TrKA-IN-1	FLT3 Trk Receptor Apoptosis	Cancer
FLT3/TrKA-IN-1 is a potent *FLT3/TrKA* dual kinase inhibitor with the IC₅₀s of 43.8 nM, 97.2 nM, 92.5 nM and 23.6 nM for FLT3, FLT3-ITD, FLT3-TKD and TrKA, respectively. FLT3/TrKA-IN-1 induces cell cycle arrest at the G0/G1 phase as well as apoptosis and shows antiproliferative activity in vitro. FLT3/TrKA-IN-1 has the potential for the research of Acute myeloid leukemia (AML) .

HY-143278

FLT3-IN-13	Topoisomerase FLT3 Apoptosis	Cancer
FLT3-IN-13 (compound 20) is a potent and effective antileukemic topoisomerase II and *FLT3* dual inhibitor with IC₅₀ values of 2.26 μM and 2.26 μM, respectively. FLT3-IN-13 arrests cell cycle at G2/M phase and induce apoptosis. FLT3-IN-13 has anticytotoxic activity, particularly against leukemia .

HY-160848

FLT3/ITD-IN-5	FLT3	Cancer
FLT3/ITD-IN-5 (Example 6) is an orally active *FLT3* and *FLT3-ITD* inhibitor, with IC₅₀ values of 0.088 and 0.348 nM, respectively. FLT3/ITD-IN-5 can be used for the research of cancer .

HY-162906

FLT3/HDAC-IN-2	HDAC FLT3	Cancer
FLT3/HDAC-IN-2 is (compound 25h) a *FLT3/HDAC* dual inhibitor. FLT3/HDAC-IN-2 has antiproliferative activity against MOLM-13 cells. FLT3/HDAC-IN-2 can be used in acute myeloid leukemia research .

HY-148036S

FLT3-IN-16-d1	Isotope-Labeled Compounds FLT3	Cancer
FLT3-IN-16-d1 is the deuterium labeled FLT3-IN-16 (HY-148036). FLT3-IN-16 is a potent *FLT3* inhibitor with an IC₅₀ of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia .

HY-169076

FLT3/HDAC-IN-1	FLT3 HDAC Apoptosis	Cancer
FLT3/HDAC-IN-1 is a dual inhibitor of *FLT3/HDAC, with IC₅₀* values of 30.4, 52.4, and 14.7 nM for FLT3, HDAC1, and HDAC3, respectively. FLT3/HDAC-IN-1 can induce apoptosis in MV-4-11 cells and has anti-proliferative effects on FLT3 mutant-transformed BaF3 cells. FLT3/HDAC-IN-1 is being researched for its potential in treating hard-to-treat solid tumors and hematological malignancies .

HY-146680

FLT3/ITD-IN-4	FLT3 RET CDK MAP4K	Cancer
FLT3/ITD-IN-4 (Compound 16) is a selective FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) inhibitor with an IC₅₀ of 2.3 nM. FLT3/ITD-IN-4 can be used for acute myeloid leukemia research .

HY-18744

FLT3-IN-2	FLT3	Cancer
FLT3-IN-2 is a FLT3 inhibitor with IC50 of ＜ 1 μM, detailed information refer to WO 2012158957 A2 and WO 2007013896.

HY-161709

FLT3/CDKs ligand-1	Ligands for Target Protein for PROTAC FLT3 CDK	Cancer
FLT3/CDKs ligand-1 (Compound 14) is a ligand for target protein, which promotes the degradation of cyclin-dependent kinase (CDK) and the FMS-like tyrosine kinase 3 (FLT3), inhibits FLT3/CDK related proliferations and survivals of leukemia cells. LT3/CDKs ligand-1 can be used for synthesis of PROTAC FLT3/CDKs degrader-1 (HY-161708) .

HY-162367

FLT3/CHK1-IN-2	FLT3 Checkpoint Kinase (Chk)	Cancer
FLT3/CHK1-IN-2 (Compound 30) is a dual inhibitor of *FLT3* and CHK1, with IC₅₀s of 25.63, 16.39, 22.80 nM for CHK1, FLT3-WT, and FLT-D835Y respectively. FLT3/CHK1-IN-2 has favorable oral PK properties and kinase selectivity. FLT3/CHK1-IN-2 can be used for research of acute myeloid leukemia (AML) .

HY-115904

FLT3/CDK4-IN-1	CDK FLT3	Cancer
FLT3/CDK4-IN-1 is a potent, high selective and orally active *FLT3/CDK4* dual inhibitor (IC₅₀=11 and 7 nM for FLT3 and CDK4, respectively). FLT3/CDK4-IN-1 has antiproliferative activities against certain cancer cells. FLT3/CDK4-IN-1 has good antitumor effect in vivo .

HY-128571

FLT3-IN-4	FLT3	Cancer
FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC₅₀=7 nM) inhibitor for treating acute myelogenous leukemia .

HY-155195

FLT3/CHK1-IN-1	Others	Cancer
FLT3/CHK-IN-1 (Compound 18) is a dual inhibitor of FLT3/CHK1. FLT3/CHK-IN-1 is more than 1700 times more selective to c-KI T and greatly reduces hERG affinity with an IC₅₀ value of 58.4 μM. FLT3/CHK-IN-1 inhibits tumor growth in mouse xenotransplantation models inoculated with MV-4-11 cells .

HY-161323

FLT3-ITD/D835Y-IN-1	FLT3 Bcr-Abl Apoptosis	Cancer
FLT3-ITD/D835Y-IN-1 (Compound 1) is a *FLT3-ITD* and BCR-ABL inhibitor. FLT3-ITD/D835Y-IN-1 mediates proapoptosis by inhibiting the FLT3 and BCR-ABL pathways, as well as other possible targets. FLT3-ITD/D835Y-IN-1 can be used in the study of acute myeloid leukemia (AML) .

HY-143434

FLT3/D835Y-IN-1	FLT3	Cancer
FLT3/D835Y-IN-1 (compound 13a) is a orally active, potent and selective *FLT3* and *FLT3/D835Y* inhibitor, with IC₅₀ values of 0.26 nM and 0.18 nM, respectively. FLT3/D835Y-IN-1 also blocks tumor growth, has anticancer efficacy, and can be used to research for AML (acute myeloid leukemia) .

HY-12960

SKLB4771 FLT3-IN-1	FLT3 c-Kit Apoptosis	Cancer
SKLB4771 is a potent and selective Flt3 inhibitor with an IC₅₀ value of 10 nM. SKLB4771 downregulates the phosphorylation of FLT3/STAT5/ERK, blocks cell proliferation, and induces apoptosis in tumor tissue .

HY-RS04987

FLT1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FLT1 Human Pre-designed siRNA Set A contains three designed siRNAs for FLT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FLT1 Human Pre-designed siRNA Set A FLT1 Human Pre-designed siRNA Set A

HY-RS04988

Flt1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Flt1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Flt1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Flt1 Mouse Pre-designed siRNA Set A Flt1 Mouse Pre-designed siRNA Set A

HY-RS04989

Flt1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Flt1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Flt1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Flt1 Rat Pre-designed siRNA Set A Flt1 Rat Pre-designed siRNA Set A

HY-RS04990

FLT3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FLT3 Human Pre-designed siRNA Set A contains three designed siRNAs for FLT3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FLT3 Human Pre-designed siRNA Set A FLT3 Human Pre-designed siRNA Set A

HY-RS04991

Flt3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Flt3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Flt3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Flt3 Mouse Pre-designed siRNA Set A Flt3 Mouse Pre-designed siRNA Set A

HY-RS04992

Flt3 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Flt3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Flt3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Flt3 Rat Pre-designed siRNA Set A Flt3 Rat Pre-designed siRNA Set A

HY-RS04994

FLT4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FLT4 Human Pre-designed siRNA Set A contains three designed siRNAs for FLT4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FLT4 Human Pre-designed siRNA Set A FLT4 Human Pre-designed siRNA Set A

HY-RS04995

Flt4 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Flt4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Flt4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Flt4 Mouse Pre-designed siRNA Set A Flt4 Mouse Pre-designed siRNA Set A

HY-RS04996

Flt4 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Flt4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Flt4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Flt4 Rat Pre-designed siRNA Set A Flt4 Rat Pre-designed siRNA Set A

HY-158265

FLT3D835Y/F691L-IN-1	FLT3	Cancer
FLT3D835Y/F691L-IN-1 (compd 8v) is an orally active inhibitor of FLT3 3-tyrosine kinase domain D835Y/F691L secondary mutations with IC₅₀s of 1.5 and 9.7 nM. FLT3D835Y/F691L-IN-1 can be used for acute myeloid leukemia research .

HY-RS04993

FLT3LG Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FLT3LG Human Pre-designed siRNA Set A contains three designed siRNAs for FLT3LG gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FLT3LG Human Pre-designed siRNA Set A FLT3LG Human Pre-designed siRNA Set A

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P99364

Icrucumab Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1	Classification of Application Fields Disease Research Fields Cancer	VEGFR
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a human Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors .

HY-107417

Hypothemycin	Structural Classification Monophenols Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Phenols Disease Research Disease Research Fields Cancer	VEGFR MEK FLT3 PDGFR ERK
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, MEK1/MEK2, *FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively .

HY-N0071

Crotonoside Isoguanosine	Alkaloids Structural Classification Classification of Application Fields Other Alkaloids Croton tiglium Linn. Source classification Euphorbiaceae Plants Disease Research Fields Cancer	FLT3 HDAC
Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits *FLT3* and HDAC3/6, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the research of AML .

HY-N10221

Petromurin C	Alkaloids Monophenols Microorganisms Classification of Application Fields Source classification Phenols Disease Research Fields Indole Alkaloids Cancer	Apoptosis
Petromurin C is a bisindolylbenzenoid compound isolated from the ascostromata of Petromycesmuricatus. Petromurin C induces protective autophagy and apoptosis in FLT3-ITD-positive AML .

Cat. No.	Product Name	Chemical Structure

HY-12432S1

Gilteritinib-d8
Gilteritinib-d₈ is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].

HY-10230S

Midostaurin-d5
Midostaurin-d₅ is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM[1].

HY-148036S

FLT3-IN-16-d1
FLT3-IN-16-d1 is the deuterium labeled FLT3-IN-16 (HY-148036). FLT3-IN-16 is a potent *FLT3* inhibitor with an IC₅₀ of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia .

HY-10260S1

Vandetanib-d4
Vandetanib-d₄ is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].

HY-10260S

Vandetanib-d6
Vandetanib-d₆ is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].

HY-10260S2

Vandetanib-13C6
Vandetanib-13C6 is a deuterated labeled Vandetanib . Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and EGFR/HER1 (IC₅₀=500 nM) .

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-108263S

3-Hydroxy Midostaurin-d5
3-Hydroxy Midostaurin-d₅ is a deuterium labeled 3-Hydroxy Midostaurin. 3-Hydroxy Midostaurin is a metabolite of PKC412, which effectively inhibits FMS-like tyrosine kinase-3 (FLT3) autophosphorylation with IC50s of approximately 132 nM and 9.8 μM in culture medium and plasma, respectively[1].

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively[1][2].

HY-10201S2

Sorafenib-13C,d3

1 Publications Verification

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks